NCT05061251View on ClinicalTrials.gov

Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma

EARLY_PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

December 1, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2023

Conditions

GliomaIDH Mutation

Interventions

DRUG

BAY 2402234

Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.